||Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE, HALT-C TRIAL GROUP, Cormier M, Giansiracusa D, Bonkovsky HL, Borders G, Kelley M, Di Bisceglie AM, Bacon B, Neuschwander-Tetri B, Brunt EM, King D, Clinical H, Dienstag JL, Chung RT, Reid AE, Bhan AK, Molchen WA, Lundmark DP, Everson GT, Trouillot T, Kugelmas M, Nash SR, DeSanto J, McKinley C, Morgan TR, Hoefs JC, Craig JR, Jamal MM, Sheikh M, Park C, Lee WM, Rogers TE, Malet PF, Shelton J, Crowder N, Elbein R, Liston N, Govindarajan S, Jones CB, Milstein SL, Lok AS, Fontana RJ, Greenson JK, Richtmyer PA, Bonham RT, Shiffman ML, Sterling RK, Contos MJ, Mills AS, Hofmann C, Smith P, Ghany MG, Liang TJ, Kleiner D, Park Y, Rivera E, Haynes-Williams V, Seeff LB, Robuck PR, Hoofnagle JH, Morishima C, Gretch DR, Apodaca MC, Shankar R, Antonov N, Snow KK, Stoddard AM, Goodman ZD, Monge F, Parks M, Davis GL, Garcia-Tsao G, Kutner M, Lemon SM, Perrillo RP, Szabo G, Banner BF
||BACKGROUND & AIMS: High-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated. METHODS: Patients (n=885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon Î±-2a (180 Î¼g/wk) and ribavirin (1000-1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n=466), and undetectable hepatitis C virus RNA at weeks 20 (n=320), 48 (end of treatment, n=284), and 72 (sustained virologic response; n=157). RESULTS: Median log10 drop from baseline to week 20 was 2.0 (interquartile range [IQR], 0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or more cups/day of coffee (P trend<.0001). After adjustment for age, race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend=.004) for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend=.005) for week 20 virologic response, 2.4 (95% CI: 1.3-4.6; P trend=.001) for end of treatment, and 1.8 (95% CI: 0.8-3.9; P trend=.034) for sustained virologic response. CONCLUSIONS: High-level consumption of coffee (more than 3 cups per day) is an independent predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis C.